Phase 3 INOpulse Trial Enrollment Completed; Results Due This Year

Phase 3 INOpulse Trial Enrollment Completed; Results Due This Year

The Phase 3 REBUILD clinical trial testing INOpulse (inhaled nitric oxide) in people with pulmonary fibrosis (PF) has enrolled its last patient. Recruitment finished sooner than anticipated, according to INOpulse developer Bellerophon Therapeutics. Top-line results are expected later this year and it’s hoped they will support efforts on…

Always Pay Attention to Your Body’s Signs

Shortly after I was diagnosed with idiopathic pulmonary fibrosis (IPF), I was on a walk and spotted a leaf in the shape of a heart. For some reason, the beauty of it struck me. It was a sign; nature had left me a message. I collected the leaf and…

This Year, I’m Making New Memories, Not Resolutions

New Year’s resolutions are an annual tradition for many of us. We make promises to ourselves to do something better in the year. But this year, I’ve decided to do something different: Instead of resolutions, I plan to make new memories. Why make resolutions I know I can’t keep? After…

DACT2 Protein at High Levels Eases Lung Scarring in IPF Mouse Models

A protein called DACT2 alleviated signs of lung scarring in mouse models of idiopathic pulmonary fibrosis (IPF), researchers reported. In tests in cells, DACT2 was found to work by suppressing glycolysis, an energy-producing metabolic process that is overactive in myofibroblasts, the cells involved in excess scar tissue formation in IPF.

New Startup Isterian Biotech Working to Develop IPF Therapies

A new startup company called Isterian Biotech has launched with the goal of developing new therapies for fibrotic diseases. Isterian is working to develop a first-in-class group of small molecules that would inhibit a protein called transglutaminase 2 (TG2), which plays a key role in fibrosis, or tissue scarring. Preclinical…